ORIGINAL RESEARCH–PEYRONIE'S DISEASE: The Use of Intralesional Clostridial Collagenase Injection Therapy for Peyronie's Disease: A Prospective, Single-Center, Non-Placebo-Controlled Study

Authors

  • Gerald H. Jordan MD, FACS, FAAP

    1. Department of Urology, Eastern Virginia Medical School, Norfolk, VA, USA; Devine Center for Genitourinary Reconstructive Surgery, Sentara Norfolk General Hospital, Norfolk, VA, USA
    Search for more papers by this author

Gerald H. Jordan, MD, FACS, FAAP, 400 W. Brambleton Avenue, Suite 100, Norfolk, VA 23510, USA. Tel: (757) 457-5125; Fax: (757) 626-0768; E-mail: ghjordan@sentara.com

ABSTRACT

Introduction.  Peyronie's disease afflicts at least 3% of sexually active men over the age of 30. Many pharmacologic therapies have been tried, but to date, no systemic or local therapy has been proven to provide predictable and lasting results.

Aim.  This study was designed to assess the efficacy and safety of intralesional clostridial collagenase injection therapy in a series of patients with Peyronie's disease.

Methods.  Twenty-five patients aged 21–75 years who were referred to a single institution with a well-defined Peyronie's disease plaque were treated with three intralesional injections of clostridial collagenase 10,000 units in a small volume (0.25 cm3 per injection) administered over 7–10 days, with a repeat treatment (i.e., three injections of collagenase 10,000 units/25 cm3 injection over 7–10 days) at 3 months. Primary efficacy measures were changes from baseline in the deviation angle and plaque size. Secondary efficacy end points were patient responses to a Peyronie's disease questionnaire and improvement according to the investigators' global evaluation of change.

Main Outcome Measure.  The primary efficacy measures were change in deviation angle and change in plaque size. Secondary end points were patient questionnaire responses and improvement according to the investigators’ global evaluation of change.

Results.  Significant decreases from baseline were achieved in the mean deviation angle at months 3 (P = 0.0001) and 6 (P = 0.0012), plaque width at months 3 (P = 0.0052), 6 (P = 0.0239), and 9 (P = 0.0484), and plaque length at months 3 (P = 0.0018) and 6 (P = 0.0483). More than 50% of patients in this series considered themselves “very much improved” or “much improved” at all time points in the study, and the drug was generally well tolerated.

Conclusion.  The benefits of intralesional clostridial collagenase injections in this trial lend support to prior studies supporting its use in the management of Peyronie's disease. A double-blind, placebo-controlled study is currently under development. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: A prospective, single-center, non-placebo-controlled study. J Sex Med 2008;5:180–187.

Ancillary